Kopinja et al. reported the discovery of a brain-penetrant IDH1-mut selective small molecule inhibitor (MRK-A) capable of potently inhibiting 2-HG production in two patient-derived orthotopic IDH1R132H-mut glioma xenograft models (BT142 and GB10) [38]. This evidence concerns the gene IDH1 and central nervous system cancer.